Latest Conference Articles

Molecular Analysis Should Guide Treatment Individualization in AML

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

Dr. Wierda on Frontline Therapy for Older CLL Patients Compared to Younger

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses the different standard frontline therapies for patients with chronic lymphocytic leukemia.

New Approaches Emerge for Treating ALL, Yet Challenges Remain

The treatment landscape for acute lymphoblastic leukemia (ALL) is changing, pointing to promising new approaches clinicians can use in practice.

Integration of Novel CLL Agents Into Frontline Setting Continues to Evolve

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

Novel Therapies in Hodgkin Lymphoma Coming to Clinics

Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

Chemotherapy for CLL Not Yet Obsolete But in Flux as New Agents Gain Ground

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Treatment Triplets Offer New Strategies in Relapsed Multiple Myeloma

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

Sequencing Therapies in Follicular Lymphoma Requires Multifaceted Approach

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

Dr. Treon on Breakthroughs in Waldenström's Macroglobulinemia

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

Dr. Sundar Jagannath Discusses Approval of Lenalidomide in Multiple Myeloma

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

Dr. Michael Mauro on Treatment Discontinuation for CML

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

Multitargeted Drug Slows CRC as Third-Line Therapy

Treatment with a multitargeted tyrosine kinase inhibitor led to a small but statistically significant improvement in progression-free survival (PFS) in patients with advanced, previously treated metastatic colorectal cancer.

Pomalidomide Shows Benefits in Trials Testing New Combinations

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

Multiple Myeloma Advances: Noted Hematologist Envisions Big Changes in Treatment Paradigms

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

Monocyte-Targeting Agent Active in Locally Advanced Pancreatic Cancer

Almost half of patients with borderline resectable or locally advanced pancreatic cancer had objective responses to treatment with an investigational chemokine receptor antagonist.

Lanreotide Effective in Pancreatic NET Subgroup

Lanreotide improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors.

Ramucirumab Improves Survival in HCC Subgroup

An analysis of patients with advanced hepatocellular carcinoma and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

Expanded NAPOLI-1 Analysis Further Characterizes MM-398 Benefit in Metastatic Pancreatic Cancer

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

Polymorphisms May Offer Clues to Treatment Outcomes in HCC

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

Dr. Wang-Gillam on PF-04136309 Plus FOLFIRINOX in Pancreatic Adenocarcinoma

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).

Dr. Manish Shah on Onartuzumab for Gastroesophageal Adenocarcinoma

Manish A. Shah, MD, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC).

Adjusted Nab-Paclitaxel/Gemcitabine Regimen Less Toxic in Pancreatic Cancer

Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.

Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine Tumors

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.

Dr. Alexandria Phan on a CLARINET Study Subgroup Analysis

The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.)

MET Inhibition Shows Some Promise in Advanced Gastroesophageal Cancer

Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.

Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Dr. Cremolini on Frontline FOLFOXIRI Plus Bevacizumab in mCRC

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.